Alcobra Ltd. Expected to Post FY2017 Earnings of ($1.00) Per Share (ADHD)
Alcobra Ltd. (NASDAQ:ADHD) – Equities researchers at Jefferies Group increased their FY2017 EPS estimates for Alcobra in a note issued to investors on Thursday. Jefferies Group analyst B. Amin now expects that the firm will post earnings of ($1.00) per share for the year, up from their prior forecast of ($1.07). Jefferies Group has a “Buy” rating on the stock. Jefferies Group also issued estimates for Alcobra’s FY2018 earnings at ($0.97) EPS, FY2019 earnings at ($1.09) EPS and FY2020 earnings at ($1.12) EPS.
Other research analysts also recently issued research reports about the stock. Zacks Investment Research raised shares of Alcobra from a “sell” rating to a “hold” rating in a report on Tuesday, July 26th. Canaccord Genuity assumed coverage on shares of Alcobra in a report on Tuesday, June 7th. They issued a “buy” rating for the company. Oppenheimer Holdings Inc. downgraded shares of Alcobra from an “outperform” rating to a “market perform” rating in a report on Thursday. Cantor Fitzgerald downgraded shares of Alcobra from a “buy” rating to a “hold” rating and set a $2.00 price target for the company. in a report on Thursday. Finally, Roth Capital reissued a “buy” rating and issued a $12.00 price objective on shares of Alcobra in a research report on Tuesday, June 21st. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and four have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $6.97.
Alcobra (NASDAQ:ADHD) opened at 2.47 on Monday. Alcobra has a 12-month low of $1.95 and a 12-month high of $8.78. The stock’s market cap is $68.08 million. The stock has a 50 day moving average price of $4.69 and a 200 day moving average price of $4.50.
Alcobra (NASDAQ:ADHD) last released its quarterly earnings data on Tuesday, August 30th. The company reported ($0.21) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.22) by $0.01.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ADHD. Stifel Financial Corp boosted its position in Alcobra by 34.2% in the second quarter. Stifel Financial Corp now owns 62,000 shares of the company’s stock worth $278,000 after buying an additional 15,800 shares during the last quarter. Jefferies Group LLC purchased a new position in Alcobra during the second quarter worth $533,000. Palo Alto Investors LLC boosted its position in Alcobra by 7.3% in the second quarter. Palo Alto Investors LLC now owns 272,788 shares of the company’s stock worth $1,225,000 after buying an additional 18,600 shares during the last quarter. BlackRock Fund Advisors boosted its position in Alcobra by 11.4% in the first quarter. BlackRock Fund Advisors now owns 354,614 shares of the company’s stock worth $1,344,000 after buying an additional 36,218 shares during the last quarter. Finally, VHCP Management LLC boosted its position in Alcobra by 28.7% in the second quarter. VHCP Management LLC now owns 623,313 shares of the company’s stock worth $2,799,000 after buying an additional 138,813 shares during the last quarter. 73.69% of the stock is owned by institutional investors.
Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse.
Receive News & Stock Ratings for Alcobra Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alcobra Ltd. and related stocks with our FREE daily email newsletter.